Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Affiliations

• ¹ Department of Thoracic Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
• ² Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY.
• ³ Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Taipei Cancer Center and Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.
• ⁴ Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong.
• ⁵ Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
• ⁶ Lung Cancer and Thoracic Cancer Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
• ⁷ Department of Oncology and Radiotherapy and Early Clinical Trials Center, Medical University of Gdansk, Gdansk, Poland.
• ⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
• ⁹ F. Hoffmann-La Roche Ltd, Mississauga, Canada.
• ¹⁰ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom. Electronic address: [email protected].